Advanced Life Sciences outlines plans for IPO

Advanced Life Sciences Holdings of Woodridge, Illinois, has outlined plans to go public with an offering of 6.4 million shares at $5 per share. Advanced Life Sciences has been developing drugs for infection, cancer and inflammation. Its lead candidate, cethromycin, is a ketolide antibiotic in late-stage clinical development for the treatment of respiratory tract infections.

- read this press release for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.